IBio And Planet Biotech Reach License Agreement For Development Of COVID-19 Therapeutic

(RTTNews) - Shares of iBio Inc. (IBIO) were gaining 14 percent in pre-market trading on Friday, after the company said it has reached an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc.

As per the terms of the deal, iBio obtained an exclusive license to Planet's ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.

In the pre-market trading, IBIO was trading at $2.42 up $0.31 or 14.69 percent.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More